Most of that time was spent in a city called Barquisimeto. Our house overlooked a valley where sugar cane was grown called "Valle del Turbio", named for a river that ran close to our house. The river, which translates to "murky", was aptly named because during dry season it was stagnant and stinky. As such, mosquitoes and the illnesses they bear were very common in our neighbourhood.
|Valle del Turbio, which separates the cities of |
Cabudare and Barquisimeto in Venezuela.
My earliest memory of someone getting dengue was probably in 7th or 8th grade when my dad got dengue, and I very vividly remember seeing him wrapped up in one of the very few blankets we owned, because it never got cold enough for blankets. My dad was lying on the sofa in front of the TV while shivering in the blistering afternoon heat. I yelled for my sister to come see because he was rambling and uttering gibberish, which I thought was hilarious. Years later, I realized that it was due to the very high fever that accompanies dengue, and understood why my mom had been so anxious and worried.
We always took precautions when there were a lot of mosquitoes: all our beds had mosquito netting hanging from hammock hooks in the walls; about 1 hour before going to bed, my dad would spray all our bedrooms with Baygon bug spray; we used plenty of insect repellent when we sat outdoors; and we never chased away the bats that lived in our mango trees, in hopes that they'd eat their share of mosquitoes at dusk. When one of us got dengue or knew of our neighbours getting it, we'd use even more bug repellent since a person who is infected with the virus can infect a mosquito when they get bitten. In the course of doing research for this piece, I've learned that most of these measures didn't matter anyway, since the mosquito that carries dengue is most active during the day.
I got dengue when I was in 9th grade and I'm the only person in my family who got it only once, probably because I lived in Venezuela for the least amount of time. I remember that my body hurt a lot, like severe growing pains. We never went to the doctor when we got dengue, but recognized it due to the pain that it caused, the high fevers, and the red dots under our skin. Even if we had gone to the doctor, there wasn't anything that could be done, so we just took Tylenol to reduce the fever and rested.
My first true scare with dengue happened when I was in my first year of college in Canada. My mom called to tell me that they had taken my sister to a clinic because she had hemorrhagic dengue. I don't think I can accurately describe the fear that this statement caused unless I give you an idea of the status of Venezuela's hospitals. A hospital in Venezuela is just a concrete building where doctors work. That's it. There are no amenities, you have to buy your own medicine, you have to bring your own sheets, there are huge line-ups, it's hot, it's disorganized, and it's noisy. So we never went to the hospital. Ever. The only time I ever went to a hospital was to visit my brother, who's a surgeon, and it was not an experience that I'd care to repeat. I once asked my sister-in-law (who is an Ob/Gyn) what had been her craziest experience in the hospital. She and my brother worked in our state's largest hospital for several years. She said that in the middle of a C-section, there had been a power outage and, of course, there was no emergency generator. So she called all her students into the OR and asked them to turn on the lights on their cell phones, and she finished her surgery to the glow of Blackberry's and iPhones. So based on that single phrase, "we've taken your sister to the clinic", I knew just how bad it had to be. Dengue causes platelet and white blood cell counts to drop, leading to an inability to clot blood and internal bleeding. Patients then go into shock and can die within 24 hrs. According to the WHO, dengue has a fairly low mortality rate: 2.5%, yet most of those who are hospitalized are young children. While doctors were deciding whether my sister needed a blood transfusion, they noted that her platelet count was rising, and she was able to recover within a few days. She wrote to me about her experience: "The nasty part of dengue was the weakness, feeling dizzy and faint all the time. When I was in the hospital I remember getting nosebleeds a lot by just touching or scratching my nose a little. That's how low my platelet levels were."
I asked my family members to describe their own experiences with dengue. Here's what my dad wrote: "I had it 2 or 3 times. The things I remember are high fever, headache, pain in joints and bones, general weakness and discomfort which would last for a relatively long time and take time to recuperate, skin rash in case of hemorrhagic dengue, and low platelets that may result in blood transfusion. In Venezuela they give you folic acid to increase platelets, a pain killer that is not Aspirin, and lots of liquid."
My brother wanted me to stress a few other points, particularly insecticide use in public areas during epidemics: DDT was used in Venezuela until fairly recently. He mentioned that Abate larvicide was used in the drinking water in places where people didn't have running water. Although it's WHO approved for drinking water, he thought "it makes it taste horrible." Finally, my sister-in-law mentioned that she remembers having patients with miscarriages during dengue epidemics.
You can imagine that I'm pretty biased and was elated to learn that a genetically modified mosquito has been approved to combat dengue in Brazil. Although the mortality rate for dengue may not be high, it carries a high cost to individuals and medical systems when there is an epidemic.
|Aedes Aegypti. Note the banding pattern on the legs.|
I was surprised that there are already several papers published on the OX513A mosquito, and as far as I could tell, all or most of the studies were (understandably) written in collaboration with Oxitec. OX513A requires tetracycline in order to survive. In the absence of Tetracycline, its offspring die at late larval or early pupal stage (details of the mechanism of action of the transgene can be found here). This antibiotic can be easily provided to the skeeters in the laboratory, but would be difficult for them to find in the wild. This was an important point for me, because as a fan of Jurassic Park, I knew that if dinosaurs were able to escape and find a source of lysine, then it might be possible for mosquitoes to find a source of food required for their survival. However, unlike lysine which is found everywhere, I couldn't find a readily available source of tetracycline in my web searches. The antibiotic is made synthetically so it is highly unlikely that the mosquitoes will ever find an abundant natural source for it. The modification for OX513A is non-sex-specific (some of the other RIDL modifications are specific to male-mosquitoes), and the mosquito also carries a red-fluorescence protein for visual identification (wouldn't it be AWESOME to see a glowing mosquito when you hear that annoying buzzing sound in the middle of the night right next to your ear!?!). However, for the purposes of the control program, only male RIDL mosquitoes will be released into the wild.
A study in 2011 compared lifespan and other metrics between the genetically modified mosquito and its wild-counterpart. It found that "unmodified mosquitoes survived on average about 5% better than the transformed OX513A line", and the unmodified mosquitoes pupated on average one day later than the modified ones. The unmodified mosquitoes were also larger and lived longer, concluding that there are statistically significant differences between OX513A and its wild-counterpart. The authors suggest several hypotheses for their findings: the silencing of the lethal gene may not be complete, the transgene may have negative effects, the transgene may have inserted itself in a region where it is impacting surrounding genes, or that the strain of mosquito is too inbred and may be expressing recessive mutations. The authors conclude that it will be necessary to determine if any of the differences observed in the OX513 mosquitoes have an impact on mating capacity (i.e. will 'normals' still find the mutants "sexy"? And unfortunately, a more rigorous study would be required than gauging audience reactions to Mystique in X-Men).
The question of mating capacity is key to the success of this entire program. I was surprised to learn that the Aedes aegypti female is monogamous, while the male is polygamous (I'm sure a scorned woman out there is probably thinking "Typical!"). So if the wild-type female were to prefer the wild-type male, then the whole project would fall apart because the mutant gene would never pass on to the next generation. A study examining mating capacity was published late 2011, and compared OX513A with it's closest wild relative. The materials and methods of this paper is really interesting: the authors set up 100 "mating arenas" for the mosquitoes and added either a wild- or mutant male to each arena. Then, they added 5 virgin females to the cages for 90 minutes a day until the males died. An alternate treatment was to not add females on the fourth and fifth day (i.e. the males got 2 days of 'rest'). The females were removed and dissected to check for the presence/absence of sperm. The key findings are that the longer the males lived, the more females they inseminated (that's sort of a 'duh' finding...). However, the wild-type males inseminated more females than the mutants, while resting had no effect. Additionally, wild-type males outlived mutants by approximately 4 days, which replicates their previous findings regarding lifespan. Resting increased the lifespan of male mosquitoes by approximately 4 days, in both mutants and wild-types. Their conclusion? "Attempting to mate therefore appears more costly in terms of energy investment to the genetically modified males." The authors find that the wild-type and mutant males mate with the same number of females in the first 3 days, suggesting that males of both strains may have the same amount of initial sperm and energy reserves, but the mutants don't regenerate their capacity as easily. They state that this would mean that mutants would have to be released into the wild more frequently and that it doesn't exclude their use in a control program. The authors didn't quantify the amount of sperm that the males released, so this might be important to examine at a later date.
I don't know how Oxitec prices their program, but if it is by the number of mosquitoes required, then this is a pretty convenient problem to have. Instead of requiring the release of males every X number of weeks/days, the findings of this paper suggest that the releases would have to be done more frequently than expected. However, I agree that it doesn't mean the control program sucks. And just to be clear, I'm speculating on the fact that this translates into greater costs to the consumer since the company's website was vague on the cost of their program.
Another important topic was the impact of the mutant mosquito on its predators, that is to say, how do the mutant proteins impact the animals who eat the mutant mosquitoes? In a paper published last year, the authors used the 2 species of the predatory Toxorhynchites (known as the "elephant mosquito") to answer this question. These large mosquitoes eat the larvae of other mosquitoes, including Aedes aegypti. The scientists' choice of organism was a smart one: they wanted an organism that would be small enough to be impacted by eating the mutants, that could be studied in the lab, and that could subsist exclusively by eating the mutants (this last point is key to the value of this study). They used 3 different diets: wild-type larvae, and mutants reared with and without tetracycline. Then they examined a variety of different parameters between the different groups.
They found that the Toxorhynchites females eating the wild larvae ate more larvae than the females eating the mutant larvae reared on tetracycline. The authors have no explanation for this statistically significant difference, particularly since it was not seen in the second species tested (it would be interesting to see if this could be reproduced, particularly with more mosquitoes. Each treatment group had ~20-30 mosquitoes for this study). All other comparisons were either equivalent, or could be explained. Most importantly, there was no difference in lifespan, development, or fecundity in the mosquitoes, and the authors conclude that the mutant mosquitoes are unlikely to impact predators in the environment.
The company also did a field test in the Cayman Islands and their results were published in 2011 in Nature Biotechnology (the paper is freely available on Oxitec's website via the link I've provided). The purpose of the paper was to determine how the mosquitoes would mate in the wild and whether the patterns they observed in the lab would carry over into the "real world". For their study, "OX513A males were released in a 10-hectare (ha) area at an average release rate of 465 males/ha/week for 4 weeks, starting on Nov. 16, 2009." They set up traps over the course of the study to determine how many of the larvae were mutants. They conclude that the mutant males can compete fairly well for mates in the "real world" (i.e. mutants are sexy!!).
The last paper I read was about the release of male mutant mosquitoes in Malaysia. The goal of the study was also to determine what happens to the mosquitoes when they are released in the wild, and was carried out in a region where there are no humans. The study, published in 2012, was approved by Malaysian regulatory agencies and was carried out in an uninhabited area. However, many public engagement activities were performed prior to the study's launch. The mosquitoes were released and monitored using nets, and several parameters were measured and compared to a control mosquito species. I thought that this sentence in the discussion was encouraging: "As with previous field releases, the transgene disappeared rapidly from the environment post-release, as expected, and was not detected more than a few hundred metres beyond the release area." Translation: the mutants don't go too far and die off (as expected).
I couldn't find any readily available studies outlining the data from Brazil's trials, but this news article states that the trials have been ongoing for 2 years and have seen a 90% drop in wild Aedes aegypti. As expected, the article also outlines opposition from environmental groups, whose concerns are:
- A small number of [mutant] female mosquitoes could also be released - and end up biting people. My perspective? At least the mutant female mosquitoes don't carry dengue. Given the choice between getting bitten by a mutant mosquito vs a dengue carrying mosquito, bring on the mutants.
- Some of the new offspring could survive by feeding on food or waste contaminated with tetracycline and therefore pass on their GM traits. Seriously? How would this happen? I'm not sure how food or waste could get contaminated with enough tetracycline so that the mosquitoes get their "fix"? Tetracycline was discovered from a soil dwelling bacteria, and the antibiotic is abundantly produced via fermentation in the lab. However, it is within the realm of possibility that a cargo truck carrying tetracycline might topple over, thereby creating pools of antibiotics that the mosquitoes could then lap up. I'll give you that.
An additional concern is the possibility that the mosquitoes will be released into the wild with no regulation. I don't think this concern is valid, based on several reasons: a) If a company releases genetically modified insects secretly into the wild, then how do they make money? b) Genetically modified living organisms are governed by the Cartagena Protocol on Biosafety, which is an "international agreement which aims to ensure the safe handling, transport and use of living modified organisms (LMOs) resulting from modern biotechnology that may have adverse effects on biological diversity, taking also into account risks to human health." As such, Oxitec has been working closely with public health organizations in each country who, after all, are their customers.
My perspective is that this company seems to have done the legwork: they started with a few publications outlining their findings, moved on to field trials where there were no inhabitants, and finally to trials where there were humans. It seems that they've done all the logical tests (note that there were several other studies on these mosquitoes that I didn't cover in this blog post) and I don't see anything missing. I don't think we can say that this is a technology that has not been tested, particularly since the lifespan of a mosquito is so short. Thousands of mosquitoes representing hundreds of generations have been tested throughout the course of the last decade, and it seems that everything is fine.
So my vote is for this technology to be adopted world-wide. During her review of this piece, my sister took it one step further: "I got an advisory from the Canadian embassy in Venezuela on this Chikunguya outbreak in Latin America. A lot like dengue, I assume the technology could be applied to this disease, too."
I think my whole family would agree on one thing: we recommend its test in the "Colinas del Turbio" neighbourhood in Barquisimeto, Venezuela :)